Alectinib shows protective and preventive effects on brain metastases, and the possible mechanism is that alectinib could not efflux from the CNS through the P-glycoprotein-mediated transporter in a study of intracranial tumor models of ALK-positive NSCLC [179, 180]. This evidence concerns the gene ALK and non-small cell lung carcinoma.